|
KMID : 1146920200500060603
|
|
Journal of Pharmaceutical Investigation
2020 Volume.50 No. 6 p.603 ~ p.612
|
|
|
Simple determination and quantification of tofacitinib, a JAK inhibitor, in rat plasma, urine and tissue homogenates by HPLC and its application to a pharmacokinetic study
|
|
Kim Ji-Eun
Park Mun-Young
Kim So-Hee
|
|
|
Abstract
|
|
|
Purpose: Tofacitinib, a janus kinase (JAK) inhibitor, was developed for the treatment of rheumatoid arthritis. To evaluate its pharmacokinetic characteristics, a simple method of quantifying tofacitinib by high-performance liquid chromatography (HPLC) was developed to estimate its concentrations in rat plasma, urine and tissue homogenates.
Methods: Hydrocortisone was used as an internal standard. The mobile phase was an isocratic system of acetonitrile: 10 mM ammonium acetate, pH 5.0 (30.5:69.5, v/v), and the flow rate was 1.0 mL/min. Chromatograms were monitored by a UV detector at 287 nm. The retention times for tofacitinib and hydrocortisone were 7.21 and 11.3 min, respectively.
Results: The lower limits of quantification for tofacitinib in rat plasma and urine were 0.01 and 0.1 μg/mL, respectively. The intraday assay precisions (coefficients of variation) were generally low; 3.69?5.88% for rat plasma and 4.21?6.18% for rat urine. The corresponding values of interday assay precisions were 5.06% and 5.46%, respectively. Accuracies ranged from 92.9 to 107%, with no interference by endogenous substances. Tofacitinib has a short half-life (39.0 min) and was widely distributed in rat tissues.
Conclusion: This HPLC method is very simple and sensitive and can be applied to future preclinical and clinical investigations of tofacitinib.
|
|
|
KEYWORD
|
|
|
Tofacitinib, JAK 3 inhibitor, HPLC, Validation, Pharmacokinetics
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|